National Institutes Of Health
Researchers to collaborate on natural killer cell-based COVID-19 treatment
Cancer death rates continue to decline, but ‘more work ahead’ toward prevention
Combined biopsy approach improves prostate cancer detection
Oral statins may improve PASI score in patients with severe psoriasis
Health officials on ‘high alert’ for AFM in 2020

In 2014, there was an unexpected surge in the number of children in the United States who experienced sudden unexplained limb weakness and paralysis, particularly after a viral illness. The seemingly new condition, now recognized as acute flaccid myelitis, or AFM, is a subset of acute flaccid paralysis.
Myeloablative conditioning may improve survival for certain patients with acute myeloid leukemia
Myeloablative conditioning prior to allogeneic hematopoietic stem cell transplantation may result in improved survival compared with reduced-intensity conditioning for patients with acute myeloid leukemia with genomic evidence of measurable residual disease, according to results of a randomized phase 3 study published in Journal of Clinical Oncology.
Black patients at higher risk for cancer-associated venous thromboembolism
Should physicians prescribe antivirals to patients at high risk for flu-related complications more than 2 days after symptom onset?

The release of the latest iteration of the Infectious Diseases Society of America guidelines on the management of influenza are a welcome addition that clinicians can employ to optimally diagnose and treat patients with influenza, an infectious disease that kills thousands of Americans annually. Of the myriad topics covered in the guidelines, one of the most important is antiviral treatments.
FDA advisory committee supports approval of Keytruda for high-risk bladder cancer

An FDA advisory committee today voted to support approval of pembrolizumab for the treatment of patients with bacillus Calmette-Guérin-unresponsive, high-risk, nonmuscle-invasive bladder cancer with carcinoma in-situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.